We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: metastatic castration-resistant prostate cancer
MedXY News
EnglishTag

metastatic castration-resistant prostate cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC
news177Lu-PSMA-617mCRPC

Baseline PSMA Total Tumor Volume Predicts Who Benefits from Adding 177Lu‑PSMA‑617 to Enzalutamide in First‑line mCRPC

By MedXY|Nov 5, 2025

In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra
news177Lu-PSMAmCRPC

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Nov 5, 2025

Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematol

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease
newsBRCA突变mCRPC

Talazoparib plus Enzalutamide Significantly Prolongs Survival in mCRPC: Final TALAPRO-2 Results Confirm Greatest Benefit in BRCA‑Altered Disease

By MedXY|Nov 5, 2025

Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223
OncologyEnzalutamidemetastatic castration-resistant prostate cancer

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

By MedXY|Oct 8, 2025

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities